Background Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries. We used estimates from the Preserving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and South Africa.
Introduction
Tuberculosis is a leading cause of morbidity and mortality worldwide. In 2015, an estimated 10·4 million new cases of tuberculosis and 1·8 million deaths related to tuberculosis disease occurred globally. 1 Intensive implementation of the Stop TB Strategy and its predecessor, directly observed treatment short-course (DOTS), led to the successful treatment of 56 million individuals with tuberculosis from 1995 to 2012, and prevented their premature deaths. 2 Despite this progress however, tuberculosis that is resistant to first-line drugs is a growing problem worldwide. Multidrug-resistant (MDR) tuberculosis, resistant to at least isoniazid and rifampicin, accounted for 480 000 cases in 2015. Of additional concern, extensively drug-resistant (XDR) tuberculosis, defined as MDR tuberculosis with additional resistance to fluoroquinolones and secondline injectable drugs, has emerged globally. 3 In 2015, 9·5% of MDR tuberculosis cases were estimated to be XDR tuberculosis. 1 Patients with MDR or XDR tuberculosis, particularly those also living with HIV infection (PLHIVs), have worse outcomes than individuals with tuberculosis that is not MDR (ie, non-MDR tuberculosis).
Drug-resistant tuberculosis is primarily driven by acquired drug resistance (ADR) during treatment and transmission of drug-resistant tuberculosis from source cases to contacts. Drug resistance might develop spontaneously in a previously drug-susceptible strain before treatment and MDR tuberculosis might develop despite completion of first-line treatment. 4 Findings from mathematical models 5 have predicted that imperfect detection and treatment of tuberculosis could generate unexpectedly high proportions of MDR tuberculosis over time, and that the proportion of XDR tuberculosis cases among the MDR cases would rise rapidly if increases in detection and treatment of MDR tuberculosis were not accompanied with a simultaneous increase in cure rates. 6 In 2000, the Stop TB Partnership and WHO formed the Green Light Committee (GLC) to increase access to high-quality medicines at greatly reduced prices and prevent further ADR by supporting countries implementing programmatic management of drugresistant tuberculosis (PMDT). 7 The Preserving Effective TB Treatment Study (PETTS) was launched in nine countries in 2005 to quantify the frequency of ADR to second-line drugs and treatment outcomes among patients with MDR tuberculosis, comparing GLCapproved and non-GLC programmes. 8 Findings from PETTS showed that treatment of MDR tuberculosis was associated with a substantial risk of ADR to second-line drugs, but GLC-approved programmes had lower ADR risk and better treatment outcomes. 9 However, whether this lower risk of ADR will assist in control of MDR or XDR tuberculosis in countries with GLC-approved programmes is unknown.
We therefore used a mathematical model to project the future burden of drug-resistant tuberculosis in four countries with a high MDR tuberculosis burden 1 and different tuberculosis epidemiology, HIV prevalence, and GLC support: India, the Philippines, Russia, and South Africa. The Philippines and Russia had GLCapproved programmes, whereas the GLC programme in India did not expand beyond a pilot phase. South Africa did not participate in the GLC initiative. Data from PETTS on outcomes of treatment of MDR tuberculosis stratified by GLC support were used to estimate ADR to second-line tuberculosis medicines with the objectives of estimation of the proportion of MDR tuberculosis among incident cases of tuberculosis, estimation of the proportion of individuals with XDR tuberculosis among incident cases of MDR tuberculosis, estimation of the proportion of MDR or XDR tuberculosis attributable to ADR, and identification of which variables most affected the incidence of MDR or XDR tuberculosis.
Methods

Study design
We developed a deterministic, population-level, compartmental model comprised of a system of ordinary differential equations based on characteristics of earlier models, and calibrated using a Bayesian approach to published reports of recent estimates of tuberculosis and MDR tuberculosis. 10, 11 The model incorporated six main tuberculosis states, subdivided by drug resistance and HIV status (figure 1). It accounted for transmission of both tuberculosis and HIV, progression of latent tuberculosis infection to active tuberculosis disease in HIV-infected and uninfected individuals, outcomes of treatment (or non-treatment) of both tuberculosis and HIV, and ADR during treatment. Population growth was incorporated to approximate UN country projections. Additional details of the model are in the appendix.
The model simulated transfer between six main states of tuberculosis: (1) uninfected or susceptible; (2) latent tuberculosis infection; (3) active tuberculosis disease; (4) See Online for appendix
Research in context
Evidence before this study We searched PubMed for articles published up to Nov 1, 2016, on studies of drug-resistant tuberculosis with the search term "(tuberculosis OR TB) AND mathematical AND model AND resistan*", and also reviewed citations of search results for additional articles of relevance. We found articles about eight mathematical modelling studies describing the emergence and spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis. Previous studies have described global predictions of replacement of tuberculosis with MDR tuberculosis, estimates of drug-resistant tuberculosis in specific cohorts such as children, and outcomes of scenario-based interventions in regions or countries with a high burden of MDR tuberculosis. We identified no study that used empirical data for acquired drug resistance to second-line antituberculosis drugs to forecast estimates of MDR or XDR tuberculosis across a range of countries with a high burden of MDR tuberculosis representing different epidemiological conditions and histories of tuberculosis control.
Added value of this study Our deterministic, compartmental model of MDR and XDR tuberculosis used data from a rigorous longitudinal study of treatment outcomes in individuals with MDR tuberculosis including rates of acquired drug resistance to forecast estimates of incident MDR and XDR tuberculosis in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and South Africa. Our results estimated that MDR and XDR tuberculosis will rise and that acquired drug resistance will be a decreasing cause of incident MDR and XDR tuberculosis in all countries in our model. To our knowledge, ours is the first analysis to incorporate empirical data about acquired resistance to second-line antituberculosis drugs to generate national estimates of MDR and XDR tuberculosis in countries with a high burden of MDR disease.
Implications of all the available evidence
Improved outcomes during treatment of drug-resistant tuberculosis are unlikely to halt the spread of MDR or XDR tuberculosis at the population level. Additional strategies to prevent transmission will be necessary to stop MDR or XDR tuberculosis in countries with a high burden of MDR tuberculosis.
active tuberculosis disease that had been detected and patient was receiving the correct treatment on the basis of the underlying drug resistance (ie, non-MDR tuberculosis versus MDR tuberculosis); (5) tuberculosis disease that had been successfully treated; and (6) tuberculosis disease that spontaneously resolved without treatment ( figure 1A ). Individuals were entered into the model in a susceptible state, where they could be exposed to people with active tuberculosis disease. On exposure, susceptible individuals could acquire latent tuberculosis infection or proceed directly to tuberculosis disease. Individuals with tuberculosis disease might spontaneously resolve, die from untreated tuberculosis, or initiate treatment for active tuberculosis. Those who initiated treatment for tuberculosis disease might be cured, die during treatment, acquire drug resistance, or become lost to follow-up and stop treatment. Individuals for whom treatment failed and who did not acquire additional drug resistance were assumed to undergo retreatment. Individuals who recovered from tuberculosis might go on to relapse. Individuals with latent tuberculosis infection and those who recovered from tuberculosis disease might be infected during contact with persons with active tuberculosis and develop tuberculosis disease again. Individuals in states other than active tuberculosis were subject to a background mortality rate.
We also modelled five subdivisions of drug resistance: no resistance to isoniazid or rifampicin; resistance to either isoniazid or rifampicin; resistance to isoniazid and rifampicin (ie, MDR tuberculosis); resistance to isoniazid, rifampicin, and either fluoroquinolones or second-line injectable drugs (ie, pre-XDR tuberculosis); and resistance to isoniazid, rifampicin, fluoroquinolones, and secondline injectable drugs (ie, XDR tuberculosis; figure 1B ). ADR could only occur during treatment for active tuberculosis disease. All tuberculosis transmission events were modelled to confer the drug resistance profile of the source case, and ADR was modelled to confer no cost to competitiveness.
A simplified HIV submodel accounted for HIV mortality, mortality due to tuberculosis disease among PLHIV, and treatment outcomes of tuberculosis-HIV coinfection ( figure 1C ). HIV transmission was modelled to occur among susceptible individuals, individuals with latent tuberculosis infection, and persons recovered from tuberculosis disease. PLHIV might initiate ART, and those on ART might stop treatment or die. PLHIV on ART were assumed to not contribute to HIV incidence. Tuberculosis states for PLHIV were similar to those for individuals without HIV infection, with the exception that active tuberculosis in PLHIV could not spontaneously resolve. PLHIV with tuberculosis were modelled to be able to transmit tuberculosis to individuals without HIV infection, and vice versa. HIV was modelled to emerge in different years for each country (appendix).
Roll-out of tuberculosis treatment and ART
Treatment for non-MDR tuberculosis and MDR tuberculosis was assumed to have become available in all modelled countries beginning in 1970 and 1990, respectively. Roll-out of non-MDR tuberculosis, MDR Probability of treatment success for MDR tuberculosis, non-GLC § 0·447-0·568 PETTS Probability of death during treatment for MDR tuberculosis, non-GLC 0·079-0·156 PETTS Probability of ADR to pre-XDR tuberculosis ¶ during treatment for MDR tuberculosis, non-GLC 0·069-0·142 PETTS Probability of ADR to XDR tuberculosis|| during treatment for MDR tuberculosis, non-GLC 0·021-0·069 PETTS Probability of treatment success for pre-XDR tuberculosis, non-GLC 0·129-0·270 PETTS Probability of death during treatment for pre-XDR tuberculosis, non-GLC 0·114-0·251 PETTS Probability of ADR to XDR tuberculosis during treatment for pre-XDR tuberculosis, non-GLC 0·280-0·453 PETTS Probability of treatment success for XDR tuberculosis, non-GLC 0·044-0·161 PETTS Probability of death during treatment for XDR tuberculosis, non-GLC 0·416-0·615 PETTS Probability of being lost to follow up during treatment for MDR, pre-XDR, or XDR tuberculosis, non-GLC 0·118-0·182 PETTS Probability of treatment success for MDR tuberculosis, GLC 0·502-0·612 PETTS Probability of death during treatment for MDR tuberculosis, GLC 0·066-0·131 PETTS Probability of ADR to pre-XDR tuberculosis during treatment for MDR tuberculosis, GLC 0·042-0·098 PETTS Probability of ADR to XDR tuberculosis during treatment for MDR tuberculosis, GLC 0·005-0·033 PETTS Probability of treatment success for pre-XDR tuberculosis, GLC 0·422-0·594 PETTS Probability of death during treatment for pre-XDR tuberculosis, GLC 0·055-0·159 PETTS Probability of ADR to XDR tuberculosis during treatment for pre-XDR tuberculosis, GLC 0·061-0·169 PETTS Probability of treatment success for XDR tuberculosis, GLC 0·191-0·460 PETTS Probability of death during treatment for XDR tuberculosis, GLC 0·117-0·359 PETTS Probability of being lost to follow up during treatment for MDR, pre-XDR, or XDR tuberculosis, GLC 0·165-0·237 PETTS Probability of relapse for successfully treated tuberculosis, HIV-negative individuals 0·011-0·021 Houben et al, 2012 21 Probability of relapse for successfully treated tuberculosis, PLHIV not on ART 0·030-0·052 Houben et al, 2012 21 Probability of relapse for successfully treated tuberculosis, PLHIV on ART 0·017-0·054 Houben et al, 2012 21 Probability of death, HIV-negative individuals Imputed from life expectancy Imputed from life expectancy Probability of death, PLHIV not on ART 0·084-0·105 Anglaret et al, 2012 22 ( Table 1 continues on next page) tuberculosis, and ART programmes was assumed to follow a sigmoidal growth curve with an inflection point of 10 years. Roll-out of DOTS and GLC-supported PMDT was assumed to follow a sigmoidal growth curve with an infection point of 5 years (appendix). ART expansion was modelled to achieve the UNAIDS target that 90% of PLHIV will receive ART by 2020. 12 The proportion of individuals with incident tuberculosis who initiated treatment appropriate to the underlying drug resistance was calibrated to recently reported case-detection rates (appendix). The proportion of tuberculosis treated under DOTS-supported programmes was calibrated to fit incident MDR tuberculosis estimates from drugresistance surveys (appendix).
Data from PETTS were used to construct proportions of outcomes based on drug resistance profiles (eg, for MDR tuberculosis, pre-XDR tuberculosis, and XDR tuberculosis) stratified by HIV status and GLC support. Values for additional variables and their 95% CIs were drawn from published scientific literature (table) . For variables without CIs, we used Wilson's method to calculate 95% CIs. 28 Proportions were transformed into rates using the exponential assumption.
Statistical analysis
We generated likelihood functions from several country-specific estimates: WHO estimates for overall tuberculosis incidence and tuberculosis incidence among PLHIV in 2000 and 2015, and percentages of incident tuberculosis cases with MDR tuberculosis and incident MDR tuberculosis cases with XDR from drug resistance surveys (appendix). Likelihood functions for each of these estimates were assumed to be independent and were multiplied to generate countryspecific joint likelihood functions. Latin hypercube sampling was used to construct 100 000 unique variable sets using uniform prior distributions for all variables. Outcomes for each variable set were generated for all countries. A likelihood value was calculated for each parameter set by applying the joint likelihood function to modelled outputs corresponding to the countryspecific estimates (prior and posterior distributions are in the appendix).
Sampling with replacement was done 100 000 times with likelihood values as sampling weights. The 2·5 and 97·5 centiles of the distribution of the 100 000 resampled outputs were used to construct prediction intervals for each country. Point estimates were derived from the median of distributions. To identify variables with the greatest effect on the modelled outputs, multivariate sensitivity analysis was done using partial-rank correlation coefficients (PRCC). PRCC measures monotonicity between a given parameter input and the outcome of interest after controlling for all other variables by calculating partial correlations of the rank-transformed inputs and outputs. Probability of death, PLHIV on ART 0·030-0·037 Anglaret et al, 2012, 22 Gabillard et al, 2013 23 Risk of stopping ART, PLHIV on ART 0·026-0·033 Anglaret et al, 2012, 22 Gabillard et al, 2013 23 Contact rate for individuals with tuberculosis 2·30-5·00 Fox et al, 2013 13 Effective contact rate for PLHIV 0·50-1·50 Assumed Hazard ratio of tuberculosis incidence, PLHIV not on ART to PLHIV on ART 2·50-3·10 Alvarez-Uria et al, 2014 25 Hazard ratio of tuberculosis treatment success, PLHIV on ART to PLHIV not on ART 1·60-7·40 Arentz et al, 2012 26 Hazard ratio of death during tuberculosis treatment, PLHIV on ART to PLHIV not on ART 0·30-0·60 Arentz et al, 2012 26 Hazard ratio of ADR during treatment, non-DOTS to DOTS 3·69-12·47 Weis et al, 1994 27 Probability of initiating proper treatment for MDR, pre-XDR, or XDR tuberculosis Calibrated Calibrated
Probability of initiating proper treatment for DS, INH-resistant, or RR tuberculosis Calibrated Calibrated Proportion of DS, INH-resistant, and RR tuberculosis treated in DOTS programmes Calibrated Calibrated
Proportion of MDR, pre-XDR, and XDR tuberculosis treated in GLC programmes Calibrated Calibrated
Proportion of PLHIV not on ART who initiate ART Calibrated Calibrated
Outcomes for HIV-negative individuals and PLHIV on ART were assumed to be equivalent. Probabilities for all events were assumed to occur in 1 year unless otherwise specified. PLHIV=people living with HIV. LTBI=latent tuberculosis infection. ART=antiretroviral therapy. DS=drug-susceptible. DOTS=directly observed treatment short-course. INH=isoniazid. MDR=multidrug-resistant. ADR=acquired drug resistance. GLC=Green Light Committee. XDR=extensively drug-resistant. *Susceptible to isoniazid and rifampicin. †Treatment duration was assumed to be 6 months for both DOTS and non-DOTS. ‡Resistant to isoniazid and rifampicin. §Treatment duration was assumed to be 18 months for both GLC and non-GLC. ¶Tuberculosis resistant to isoniazid, rifampicin, and either fluoroquinolones or second-line injectable drugs. ||Tuberculosis resistant to isoniazid, rifampicin, fluoroquinolones, and second-line injectable drugs.
Table: Description of main variables and corresponding ranges used for the mathematical model
tuberculosis in 2040 were identified. All analyses were programmed in R version 3.2.1.
Role of the funding source
The US Agency for International Development (USAID) had no role in study design, implementation, data collection, data analysis, data interpretation, or writing of the report. The US Centers for Disease Control and Prevention (CDC) led the model design, data collection, data analysis, data interpretation, and writing of the report. The corresponding author had full access to the data in the study and had final responsibility for the decision to submit for publication.
Results
The percentage of incident tuberculosis cases with MDR increased in all modelled countries from 2000 to 2040 (figure 2). By the end of the time horizon, MDR tuberculosis among incident cases of tuberculosis was estimated to be 12·4% (95% prediction interval 9·4-16·2) in India, 8·9% (4·5-11·7) in the Philippines, 32·5% (27·0-35·8) in Russia, and 5·7% (3·0-7·6) in South Africa. Similarly, the percentage of incident MDR tuberculosis with XDR was estimated to increase for all countries, reaching 8·9% (5·1-12·9) in India, 9·0% (4·0-14·7) in the Philippines, 9·0% (4·8-14·2) in Russia, and 8·5% (2·5-14·7) in South Africa in 2040. The results of the sensitivity analysis suggested that MDR tuberculosis is mostly driven by common factors across countries (figure 4). The proportion of individuals initiating appropriate treatment for non-MDR tuberculosis, the hazard ratio of ADR during treatment of non-MDR tuberculosis for non-DOTS relative to DOTS, the probability of treatment failure during DOTS, and the probability of ADR during treatment of non-MDR tuberculosis were positively associated with the proportion of MDR tuberculosis among incident cases of tuberculosis. Transmission of tuberculosis to HIV-negative contacts was positively associated with incident MDR tuberculosis in most countries; tuberculosis transmission to PLHIV contacts was associated with incident MDR tuberculosis in South Africa. The proportion of individuals initiating treatment for MDR tuberculosis and the proportion of DOTS coverage were negatively associated with incident MDR tuberculosis.
Several transmission and treatment variables were associated with the percentage of XDR among incident MDR tuberculosis (figure 4). ADR during treatment for MDR tuberculosis in HIV-negative people was associated with incident XDR tuberculosis in countries with and without GLC-approved programmes. The proportion of individuals initiating appropriate treatment for MDR tuberculosis was a significant driver of cases of incident XDR tuberculosis in most countries. In South Africa, transmission of tuberculosis among PLHIV contacts and treatment outcomes among PLHIV based on ART status were positively associated with incident MDR and XDR tuberculosis, whereas LTBI reactivation was negatively associated with these tuberculosis subgroups. Tuberculosis transmission was the major driver of incident XDR tuberculosis in India and the Philippines, and exposure to MDR tuberculosis treatment was positively associated with incident XDR tuberculosis in most countries. Among countries with GLC-approved PMDT, the proportion of MDR tuberculosis treated under GLC-approved conditions was inversely related with XDR tuberculosis burden. DOTS coverage was inversely related to the percentage of incident XDR tuberculosis across countries.
Discussion
In this study, we adapted recent mathematical models of tuberculosis to forecast trends of MDR and XDR tuberculosis in India, the Philippines, Russia, and South Africa-four countries with a high burden of MDR tuberculosis that represents a wide range of epidemiological conditions. We estimated that the proportion of MDR tuberculosis among incident cases of tuberculosis, and the proportion of XDR tuberculosis among incident MDR tuberculosis will increase in all modelled countries. We identified that most incident MDR tuberculosis is not caused by ADR, and that ADR will become a decreasing cause of incident MDR and XDR tuberculosis over time, regardless of whether a country's MDR tuberculosis treatment programmes operate under GLC-approved conditions. Our observations suggest that incident MDR and XDR tuberculosis will increase despite improvements in ADR achieved by GLC-supported PMDT.
Our analysis builds on previous studies that modelled drug-resistant tuberculosis by using data about treatment outcomes from a rigorous multisite, prospective cohort study to generate country-specific forecasts for MDR and XDR tuberculosis. Country-specific projections for the percentages of incident MDR and XDR tuberculosis are consistent with aggregate findings described by Blower and colleagues. 5 Our finding that ADR is a decreasing cause of incident MDR tuberculosis is similar to results described by Kendall and colleagues. 10 To our knowledge, our study is the first to express and project trends of incident XDR tuberculosis caused by ADR using empirical data about treatment outcomes of individuals with MDR tuberculosis.
The results of this study define the expected trajectories for MDR and XDR tuberculosis in the context of the availability of new treatment regimens for non-MDR and MDR tuberculosis since 1970 and the subsequent genesis of tuberculosis strains with varying degree of drug resistance. The emergence of MDR tuberculosis occurred because of broadening availability of first-line drugs. As prevalence of MDR tuberculosis increased, the primary driver of incident MDR tuberculosis shifted from ADR during treatment to transmission to contacts of individuals with MDR tuberculosis. The benefits of DOTS expansion, which is efficient at reducing non-MDR tuberculosis, might have the unintended consequence of facilitating the spread of MDR and XDR tuberculosis due to decreased transmission of lessresistant tuberculosis strains. Similarly, XDR tuberculosis is a recent form of MDR tuberculosis that emerged due to expanded availability of second-line drugs for MDR tuberculosis. Our model suggests that as prevalence of XDR tuberculosis increases, increasing proportions of incident XDR tuberculosis will be caused by person-to-person transmission. Expansion of tuberculosis treatment programmes might reduce the overall incidence, but new cases of tuberculosis will become increasingly resistant as strains with lower resistance contribute less to transmission on a population scale.
Our findings have several implications for MDR tuberculosis. First, national tuberculosis programmes in countries with a high MDR tuberculosis burden should recognise that improved treatment outcomes conferred by GLC-approved PMDT might reduce, but will not eliminate, MDR tuberculosis resistant to second-line medicines. Implementation of GLC-approved PMDT might slow the rise of XDR tuberculosis in countries operating in non-GLC approved conditions. Second, the proportion of incident MDR tuberculosis will increase despite improved access to MDR tuberculosis treatment if there are no improvements in access to and enrolment in DOTS treatment programmes for non-MDR tuberculosis. LTBI treatment with isoniazid or rifampicin will reduce the incidence of non-MDR tuberculosis but at the consequence of increasing MDR and XDR tuberculosis as fewer non-MDR tuberculosis LTBI reactivate and subsequently contribute to person-toperson transmission. Next, to reduce burden of MDR and XDR tuberculosis, treatment of MDR tuberculosis must be coupled with methods to prevent general transmission of tuberculosis, including early detection, reducing the risk of pretreatment loss to follow-up among individuals diagnosed with tuberculosis, screening contacts for tuberculosis, and initiating proper treatment based on universal drug susceptibility testing.
The evidence for the fitness cost of ADR is mixed. Findings from in-vitro studies have shown that ADR confers a cost to competitive fitness but that MDR strains with low or no cost to fitness are the most commonly identified in clinical isolates. 29 Contact investigations examining LTBI or active disease among household contacts of individuals with tuberculosis have shown lower, equal, and higher fitness of resistant strains. 13, 30 Considering this conflicting evidence, we chose to model a scenario in which ADR does not confer a penalty to fitness at a population level. Our model was calibrated to published estimates from several sources including reports from health ministries, World Bank, and WHO. The accuracy of our estimates is contingent on the accuracy of sources used for calibration. Our model did not account for possible systematic bias in published estimates to which modelled outputs were calibrated. In India and Russia, percentages of incident MDR and XDR tuberculosis used for calibration are based on subnational drug resistance surveys that might not represent nationwide MDR and XDR tuberculosis burden. Our study highlights the need for serial, nationally representative surveys to better track the spread of drugresistant tuberculosis. Although we used a Bayesian approach to quantify uncertainty in our estimates, our findings are based on a single model structure. Alternative model structures that simulate tuberculosis transmission and ADR during treatment should be considered and compared with our results to better identify which factors drive MDR and XDR tuberculosis. We collapsed compartments for new and retreatment tuberculosis cases because of few data for clinical outcomes for MDR and XDR tuberculosis by previous treatment status. Differences in treatment outcomes for new compared to retreatment cases might have affected our estimates. Last, we did not consider changes in ecological factors, such as the human development index, population density, and migration that might affect tuberculosis transmission and estimates of MDR and XDR tuberculosis burden.
In summary, our findings suggest that the tuberculosis subgroups of MDR and XDR tuberculosis will become more common, given current treatment regimens and control methods. Expanding coverage for treatment of MDR tuberculosis will decrease the proportion of MDR tuberculosis among incident cases of tuberculosis, but at the expense of rising XDR tuberculosis. Our results also showed that improved treatment outcomes conferred by GLC-approved programmes might reduce acquired resistance to second-line drugs, but are unlikely to drive down the incidence of MDR tuberculosis, and do not appear to halt the rise of XDR tuberculosis at the population level. The results also suggest that current tools are insufficient to reverse the epidemics of MDR or XDR tuberculosis. Enhanced interventions to reduce tuberculosis transmission and expansion of improved treatment to minimise the risk of ADR are necessary to stop the spread of MDR and XDR tuberculosis.
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Drug-resistant tuberculosis threatens WHO's End-TB strategy
In the Lancet Infectious Diseases, Aditya Sharma and colleagues 1 used a compartmental model to forecast the increase of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in 2040 in four countries with an already high burden of tuberculosis: India, the Philippines, Russia, and South Africa. Their model predicted an increase in the percentage of MDR tuberculosis among incident cases of tuberculosis, reaching 12·4% (95% prediction interval 9·4-16·2) in India, 8·9% (4·5-11·7) in the Philippines, 32·5% (27·0-35·8) in Russia, and 5·7% (3·0-7·6) in South Africa in 2040. The investigators also predicted an increase in the percentage of XDR tuberculosis among incident MDR tuberculosis, reaching 8·9% (95% prediction interval 5·1-12·9) in India, 9·0% (4·0-14·7) in the Philippines, 9·0% (4·8-14·2) in Russia, and 8·5% (2·5-14·7) in South Africa in 2040.
WHO's End TB strategy sets targets to eliminate tuberculosis at a global level. According to this strategy, a 95% reduction in the number of deaths from tuberculosis and a 90% reduction in the incidence of tuberculosis should be achieved by 2035, compared with 2015. An important component of the road map for the elimination of tuberculosis is preventing the spread of drug-resistant tuberculosis, especially in the 30 countries with the highest burden of tuberculosis. 2 India, China, and Russia accounted for 45% of the cumulative total of 580 000 MDR tuberculosis cases in 2015, 3 but the highest prevalence of MDR tuberculosis was in 18 countries in Europe with a high burden of tuberculosis. 4 The most important issue in the European region has been an increase of up to 23% of XDR tuberculosis among patients with MDR tuberculosis given second-line drug susceptibility tests (DST). 5 The main problem of preventing the spread of tuberculosis in Africa and Asia is the combination of tuberculosis and HIV co-infection. In South Africa, 157 505 patients known to be HIV-positive comprised 57% of all new tuberculosis cases in 2015.
3 MDR tuberculosis can spread at a higher rate among HIV-infected patients, since not all patients receive the proper treatment regimen and they are also immunocompromised. HIV-positive patients are more prone to develop acquired drug resistance (ADR) during the treatment of tuberculosis than those who are HIV-negative. In other regions of the world, DST coverage among patients with tuberculosis is scarce because of the shortage of private health-care providers and financial and human resources. In the Philippines, 1% of new cases and 45% of previously treated cases of tuberculosis were tested for rifampicin resistance in 2015.
3 Therefore, despite the attempts to improve the epidemiological situation for tuberculosis, MDR and XDR tuberculosis is spreading globally.
The directly observed treatment short-course (DOTS) strategy for management of MDR and XDR tuberculosis is the first basic element of tuberculosis control. The absence of patients' access to the essential set of quality antituberculosis drugs and the formation of ADR as a result of inappropriate treatment might be the main obstacles to ending the global tuberculosis epidemic. All countries should meet their medication needs to reduce the annual number of patients with tuberculosis. Many developing countries do not allocate funds to provide free care to such patients, and even middle-income countries do not provide patients with tuberculosis with all the necessary medicines. The Global Fund, which acts as a partnership involving governments, civil society, the private sector, and people living with diseases, provides drugs to many countries that do not allocate the necessary funds for the purchase of medicines; 6 however, obtaining antituberculosis drugs from the Global Fund followed by inappropriate use of these drugs without following WHO guidelines can lead to an escalation of drug-resistant tuberculosis. 7 To prevent the spread of MDR and XDR tuberculosis, and ensure the correct use of drugs provided by the Global Fund, the Stop TB Partnership and WHO established the Green Light Committee (GLC) in 2000. GLC supports countries implementing programmatic management of drug-resistant tuberculosis (PMDT) to increase access to high-quality medicines at reduced prices and prevent further ADR. GLC experts assist national tuberculosis programmes in applying the most successful PMDT to provide universal access to diagnosis, treatment, and prevention of MDR tuberculosis. The GLC is particularly important now, since the percentage of MDR tuberculosis among new cases of tuberculosis and cases of retreatment is increasing in all countries-100 000 patients with MDR tuberculosis were treated after approval of national PMDT by GLC 
